See What's Inside
Read this FREE issue now
For healthcare professionals only
  • Eating Well (or at Least Not terribly) at Fast Food Resturants
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

Easy to Use Insulin Delivery Patch

Anna Tucker

Easy to Use Insulin Delivery Patch

sulfonylurea Archives

sulfonylurea

Updated 79 weeks ago
 
Novo Says Early Use of Victoza Aids Type 2 Control

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)

Comments 2 comments - Dec 15, 2011 - * * * * *

A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes

Combination therapy, in which doctors prescribe more than one drug to treat type 2 diabetes, is a fairly common practice. However, most newly diagnosed type 2 patients start off with metformin or a sulfonylurea and don't go on a two-drug therapy until their first drug begins to lose its effectiveness.

But combination therapy could soon become an earlier option for people with type 2.

Comments 2 comments - Sep 7, 2011 - * * * * *

Danish Study Reports Three Diabetes Drugs Best for Lowering Cardiovascular Risk

A Danish study of 107,806 adults taking various diabetes medications has found that three drugs are the most effective at lowering the risk of cardiovascular disease and death: metformin, gliclazide (not marketed in the US), and repaglinide (Prandin). Other common diabetes medications, including glimepiride, glibenclamide (glyburide), glipizide, and tolbutamide, were linked to a higher risk of death both from all causes and from heart attack and stroke.  

Comments 1 comment - May 13, 2011 - * * * * *

 
©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.